Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06968988 · ClinicalTrials.gov registry record · Phase 1
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
A Phase 1 study of Metastatic Soft Tissue Sarcoma, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06968988 is a Phase 1 study of Metastatic Soft Tissue Sarcoma that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 18 participants, below the 139-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06968988, a Phase 1 study of Metastatic Soft Tissue Sarcoma, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma histologies.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Zanzalintinib
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2031-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06968988
The ClinicalTrials.gov registry entry for NCT06968988 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (87% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT06968988 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06968988 about?
NCT06968988 is a clinical study titled "Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma". The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, ...
What is the current status of trial NCT06968988?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-01-05. Estimated completion is 2031-07-31.
What conditions does trial NCT06968988 study?
This clinical trial studies the following conditions: Metastatic Soft Tissue Sarcoma.
What interventions are being tested in trial NCT06968988?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06968988?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06968988 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
RECRUITING · Phase 1
-
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
RECRUITING · Phase 1
-
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.